Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07483749
Starting soon Observational

HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors

NCT07483749 · tracked via the Priya Life Science China tracker
Sponsor
The Children's Hospital of Zhejiang University School of Medicine
Phase
Observational
Started
2026-03-25
Last updated
2026-03-19

Condition(s) studied

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaLymphomaLeukemiaPediatric

Study summary

This study aims to construct a structuralized follow-up model for survivors of childhood hematological malignancies in China. Using a multicenter prospective cohort design, it will identify the burden and risk factors of late effects. The study hypothesizes that a standardized follow-up path managed by an electronic platform will improve follow-up compliance and reduce the missed diagnosis rate of late effects.

Eligibility

Sex
ALL
Min age
1 Year
Max age
21 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosed with childhood hematological malignancies (ALL, AML, Lymphoma, etc.), Completed primary treatment for ≥12 months. * Age 1-21 years. * Capable of completing follow-up and data collection. * Informed consent signed. Exclusion Criteria: * Severe organ failure preventing follow-up. * Major genetic or systemic diseases affecting growth/organ function. * Expected poor compliance or refusal to participate.

Primary outcome measure(s)

  • Incidence of severe late-effect composite endpoint. — From the date of enrollment to the end of follow-up (up to 36 months).
    The incidence of grade 3-5 chronic health conditions, including severe cardiovascular events (e.g., heart failure), new-onset diabetes, pathological fractures, severe cognitive/psychological impairment, and second primary malignancies.
  • Compliance rate of the structured follow-up mode. — Throughout the study period (24-36 months).
    The percentage of participants who complete the scheduled follow-up visits and examinations according to their assigned risk level. The target compliance rate is ≥80%.

Trial sites (3)

FacilityCityRegionStatus
Children's hospital, Zhejiang University School of Medicine Hangzhou Zhejiang
Hangzhou Children's Hospital Hangzhou Zhejiang
Affiliated Women and Children's Hospital of Ningbo University Ningbo Zhejiang

More The Children's Hospital of Zhejiang University School of Medicine trials in China

Xenon Therapy for Children With Autism Spectrum Disorder Starting soon
Effects of Enteral Feeding Regimens on NEC, Mortality, and Neurodevelopment in Very Preterm Infants Recruiting
The Efficacy of Specific Immunotherapy Guided by Component-Resolved Diagnosis for Dust Mite Allergens in Chinese Pediatric Patients With Rhinitis and/or Asthma Recruiting
Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival Recruiting
Urethral Plate Flap vs. Tunica Vaginalis Flap for Residual Severe Ventral Curvature in Hypospadias Starting soon

Other trials for the same condition

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL Recruiting
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients Recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML Active, not recruiting
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma Recruiting
Remimazolam and Emergence Delirium in Pediatrics Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07483749 on ClinicalTrials.gov ↗ ← All trials in China